Camlin Fine Sciences Ltd. (CAMLINFINE) — Tipsheet

Camlin Fine's top R&D scientist resigns citing personal commitments

Tipsheet Editorial — Tue, 07 Jul 2026 22:50:37 GMT

Anvarhusen Bilakhiya, VP – Principal Scientist and designated senior management, quits after a three-month notice. No strategic disruption is expected.

What’s new

Resignation of VP – Principal Scientist (R&D) Anvarhusen Bilakhiya.
Effective July 7, 2026, after serving three-month notice tendered on April 8.
No indication of strategic disruption; role is non-C-suite.

Why it matters

While the loss of a senior R&D leader could slow innovation, the orderly transition and non-C-suite nature limit the immediate impact. For a mid-cap chemicals company with a market cap of ₹2,619 cr, this is a moderate management change.

What we’re watching

Whether a replacement is named in the coming months.
Any commentary on R&D pipeline continuity in the next earnings call.
If further senior departures follow.

The full read

Camlin Fine Sciences’ R&D chief is leaving, but the move looks orderly, not alarming. Anvarhusen Bilakhiya, Vice President – Principal Scientist (R&D) and designated senior management, resigned on April 8 and served a full three-month notice period, making his exit effective July 7. The company cited personal commitments. The analyst note flags this as a moderate event — the role is not C-suite, and there is no indication of broader strategic disruption. For a chemical company with a ₹2,619 cr market cap and a high-trailing P/E of 94.8, R&D leadership matters, but the recent story has been about vanillin pricing and core profitability, not a single scientist. The departure removes a key figure, but the three-month runway suggests a smooth handover. The open question is whether Camlin names a replacement quickly and maintains its innovation pipeline without missing a beat.

Primary source: BSE · NSE

Camlin Fine Sciences cuts vanillin price guidance as costs surge

Tipsheet Editorial — Tue, 26 May 2026 18:56:05 GMT

Logistics disruptions clipped Q4 revenue by 20%, while management warns of higher raw material costs despite lower US tariffs.

What’s new

Vanillin realizations are now guided at $13.50-$14 per kg, missing prior expectations.
Phenol costs have doubled, while glyoxylic acid and caustic prices have more than doubled.
Cash drain from discontinued operations is set to hit ₹7-8 crore in FY25.

Why it matters

The company is struggling with a classic margin squeeze where input costs are rising faster than pricing power. Even with US tariffs dropping to 15.5%, the downward revision on vanillin suggests that competitive pressures or supply gluts are overriding the tariff benefit. Investors should watch if the 12-14% EBITDA margin target holds up against these volatile raw material prices.

What we’re watching

Whether the 3,000-ton catechol inventory is enough to buffer against further price spikes.
If the blends business hits the ₹1,400 crore revenue target.
Any further updates on the liquidation costs of the European operations.

The full read

Camlin Fine Sciences is navigating a difficult cost environment. Logistics disruptions already cost the company 20% of its revenue in Q4. Now, management faces a surge in raw material costs, with phenol prices doubling and glyoxylic acid and caustic prices more than doubling. Despite US tariffs falling to 15.5%, the company lowered its FY25 vanillin realization guidance to $13.50-$14 per kg. Management is targeting consolidated revenue of ₹2,200-2,400 crore for FY25 with EBITDA margins of 12-14%. The blends business is expected to contribute ₹1,400 crore to that total. To manage the volatility, the company is relying on a 3,000-ton catechol inventory, which it expects will last 8-9 months. Meanwhile, the cash drain from discontinued operations is expected to fall to ₹7-8 crore, a reduction from the ₹50-60 crore previously eliminated following the liquidation of European assets. The next test is whether these margins can survive the current input cost inflation.

Primary source: BSE · NSE

Camlin profit on Italian sale masks a still-lossmaking core

Tipsheet Editorial — Tue, 26 May 2026 16:58:43 GMT

Consolidated profit of ₹2,762.72 lakh came from liquidating CPS Europe SpA and adding Vinpai. Standalone losses narrowed but the core business is still in the red.

What’s new

Standalone net loss improved to ₹3,296.62 lakh from a prior-year loss of ₹7,631.05 lakh.
Consolidated net profit was ₹2,762.72 lakh, boosted by liquidating CPS Europe SpA and including Vinpai.
Board approved a new CFO and re-designated the current one.

Why it matters

The headline profit masks a still-lossmaking core. The gain came from selling an Italian subsidiary, not from the core business. The CFO change signals a reset in financial leadership.

What we’re watching

Whether the standalone loss can be turned into profit without one-off gains.
The recurring contribution from Vinpai once the initial consolidation boost fades.
Any further asset sales following the CPS Europe liquidation.

The full read

Camlin Fine Sciences' standalone net loss narrowed to ₹3,296.62 lakh from ₹7,631.05 lakh a year ago. That is a real improvement, but it is still a loss. The headline consolidated profit of ₹2,762.72 lakh tells a different story. It was powered by a gain from selling its Italian subsidiary, CPS Europe SpA, and adding Vinpai to the books for the first time. Those are one-off events, not a reflection of the core chemicals and preservatives business. The CFO shuffle adds another layer. Appointing a new finance chief while re-designating the old one signals a reset. The core question is whether management can turn a shrinking loss into real profit without relying on asset sales.

Primary source: BSE · NSE

Camlin Fine Sciences cuts standalone losses, but revenue also shrank

Tipsheet Editorial — Tue, 26 May 2026 16:43:42 GMT

Standalone net loss narrowed sharply in FY26, but the improvement came from lower revenue, not growth. Consolidated profit was a one-off from a European liquidation.

What’s new

Standalone net loss narrowed to ₹3,296.62 lakh in FY26 from ₹7,631.05 lakh in the prior year.
Standalone revenue declined to ₹83,791.82 lakh from ₹88,649.13 lakh.
Consolidated net profit of ₹2,762.72 lakh was driven by a gain from CPS Europe liquidation.

Why it matters

The loss reduction is welcome, but it was achieved on a smaller revenue base, suggesting cost cuts rather than a sales rebound. The consolidated profit is non-recurring, masking the fact that the core standalone operations are still deep in the red.

What we’re watching

Whether standalone losses continue to narrow in FY27 on an organically growing top line.
The rationale behind the simultaneous CFO appointment and re-designation.
How consolidated results look once the CPS Europe liquidation gain is no longer a factor.

The full read

Camlin Fine Sciences' FY26 results show a company cutting its standalone losses but not yet growing. The standalone net loss fell to ₹3,296.62 lakh from ₹7,631.05 lakh the year before, a material improvement. But standalone revenue also shrank to ₹83,791.82 lakh from ₹88,649.13 lakh, meaning the better bottom line came from a smaller top line. At the consolidated level, the company posted a profit of ₹2,762.72 lakh. That number, however, is a one-off, driven by a gain from the liquidation of CPS Europe. Strip out that discontinued-operation event and the core business remains loss-making. The board also approved a new CFO and re-designated the existing one, adding a layer of management change to an operational story that is still about managing decline, not reversing it.

Primary source: BSE · NSE